How is COVID-19 impacting payers and HTA decisions across the EU? What are the implications for patient access for new pharmaceutical products?
Given the unprecedented global shutdown occurring in response to COVID-19, payers and HTA bodies are struggling to adjust to the new way of working. What impact is this having on existing drugs that are currently undergoing pricing, reimbursement and health technology assessments? How has each country adapted to the challenges?
Summary of how HTA bodies decision making for new medicines are affected by COVID-19
UK: The National Institute for Health and Care Excellence (NICE)
NICE have announced they are stopping all non-critical NICE assessments. Only “therapeutically critical” assessments and COVID-19 diagnostic or therapeutic interventions will be undertaken in the short term, due to the pressures put on the NHS. In practice, this means all cancer medicines and a selected few non-cancer medicines. Technology Appraisal committee meetings are continuing to be held (except for April). However, these […]